April 01, 2021 - 1 min read
The endocannabinoid system (ECS) has a fairly unique function in the body. In many ways, it serves to regulate homeostasis, by modulating the release of other neurotransmitters, which may be excitatory or inhibitory. Besides its own ligands, the ECS interacts with most of the major neurotransmitters including acetylcholine, dopamine, GABA, histamine, serotonin, glutamate, norepinephrine, prostaglandins, and opioid compounds. The specific action of different cannabinoids (both endogenous, phyto, and synthetic) can be explained by their differential action on receptor subtypes. For example, activation of receptors in the gastrointestinal system may cause increased appetite, while suppression of those receptors would cause decrease in appetite. Similarly, different cannabinoids cause different effects on the CB2 receptors found in the immune system, which is why some activate the immune system and others suppress it.
The widespread locations and interactions of the ECS presents enormous potential for healthier living solutions. Cannabinoids have shown promise in a broad range of diseases, reflecting the presence of cannabinoid receptors in every organ system and almost every tissue in the body, and many more are likely to be elucidated as the science advances. By tailoring cannabinoid therapeutics to target only specific receptor subtypes, more targeted effects are feasible. This type of approach is nearly impossible when using plant-based extracts, as the concentration and purity of the cannabinoid composition is highly variable. With advances in semi-synthetic methods, PureForm is able to create highly purified, highly specific cannabinoids and combine them at optimal ratios to achieve the desired effects.
|Subtotal|| $ 0.00|